WTEYA MVR Evaporator Commissioning in Uruguay: Pharmaceutical Laboratory Wastewater Treatment Success

WTEYA has successfully completed the commissioning of two MVR evaporator systems for a pharmaceutical testing laboratory in Uruguay — marking another milestone in our growing presence across Latin America. The project demonstrates how WTEYA's MVR technology delivers reliable, energy-efficient wastewater treatment even for the most complex effluent profiles.

Project Background: Pharmaceutical Testing Laboratory in Uruguay

The client operates a pharmaceutical testing laboratory that conducts drug analysis and quality control for local pharmaceutical manufacturers. This type of facility generates a highly variable wastewater stream — a complex mixture of organic solvents, trace pharmaceutical compounds, salts, and biological reagents that cannot be discharged into municipal sewers without advanced treatment.

Uruguay's environmental regulations, aligned with international pharmaceutical industry standards, require such laboratories to achieve near-zero liquid discharge (ZLD) or meet stringent discharge limits before releasing any effluent. For this client, the challenge was twofold:

• Complex effluent composition: Multiple contaminant types (organic, inorganic, biological) in varying concentrations depending on the testing activities being conducted
• Variable daily flow rates: Laboratory wastewater volumes fluctuate significantly based on testing schedules and project cycles
• Regulatory compliance: Uruguay's environmental authority (DINAMA) requires pharmaceutical wastewater to meet specific quality thresholds before discharge

After evaluating several treatment approaches — including chemical precipitation, biological treatment, and conventional thermal evaporation — the client selected WTEYA's MVR evaporator technology for its energy efficiency, compact footprint, and proven track record with pharmaceutical effluent worldwide.

Two MVR Evaporator Systems: A Comprehensive Solution

WTEYA designed and delivered two complementary MVR evaporator systems to address the laboratory's full wastewater treatment requirements:

System 1: Primary MVR Evaporator — Concentration and Volume Reduction

The first MVR unit serves as the primary concentration stage, reducing the raw wastewater volume by up to 80-90%. Key operational parameters:

• Capacity: Designed for the laboratory's peak daily flow with 30% buffer capacity for flow variability
• Energy consumption: 30-60% lower than conventional multi-effect evaporators, leveraging mechanical vapor recompression technology
• Operating temperature: Low-temperature evaporation (70-85°C) to prevent degradation of volatile pharmaceutical compounds
• Distillate quality: Clean condensate suitable for reuse in laboratory non-critical processes (equipment washing, cooling circuits)

System 2: Secondary MVR Crystallizer — Salt Recovery and ZLD Achievement

The concentrated effluent from System 1 is fed into the second MVR crystallizer, which achieves final solidification and zero liquid discharge:

• Crystallization output: Dry salt crystals that can be disposed of safely or, in some cases, recovered for industrial reuse
• Complete ZLD: No liquid effluent remaining — the laboratory achieves 100% water recovery or safe solid disposal
• Automated operation: Smart PLC control manages feed rate, temperature, and crystallization cycles autonomously

The two-system configuration ensures that regardless of the laboratory's daily testing volume or effluent composition, every drop of wastewater is treated to compliance standards. This redundancy and flexibility is critical for pharmaceutical facilities where regulatory non-compliance can result in operational shutdowns.

Commissioning Process and Results

The commissioning process, conducted by WTEYA's technical team on-site in Uruguay, proceeded through three phases:

Phase 1 — Pre-commissioning (Week 1): System installation verification, piping integrity testing, and electrical/control system checkout. All connections were confirmed leak-free, and the PLC control system was calibrated against local power supply parameters.

Phase 2 — Wet testing (Week 2): Progressive introduction of actual laboratory wastewater at increasing flow rates. The MVR evaporator systems were tested across three operating scenarios:

• Low-flow conditions (typical overnight testing schedule)
• Normal-flow conditions (standard daily testing operations)
• Peak-flow conditions (batch testing campaigns with maximum wastewater generation)

Phase 3 — Performance validation (Week 3): Continuous 72-hour operation at design capacity, with daily sampling and analysis of distillate quality and crystallized solids. Results confirmed:

• Distillate quality: Met Uruguay's pharmaceutical wastewater discharge standards across all parameters (COD, BOD, TDS, trace pharmaceuticals)
• Volume reduction: 87% average volume reduction in System 1
• ZLD achievement: 100% liquid elimination confirmed in System 2 — zero liquid discharge achieved consistently
• Energy efficiency: Actual energy consumption measured at 30-60% below conventional thermal evaporation benchmarks
• System stability: No unplanned shutdowns during the 72-hour validation period

Why MVR Evaporator Technology for Pharmaceutical Wastewater

Pharmaceutical wastewater presents unique treatment challenges that conventional methods often cannot address comprehensively. MVR evaporator technology offers several decisive advantages:

• Universal contaminant removal: MVR evaporation is not selective — it removes organic compounds, inorganic salts, trace pharmaceuticals, and biological agents simultaneously through physical separation
• Energy efficiency: Mechanical vapor recompression recycles the latent heat of evaporation, achieving 30-60% energy savings compared to steam-driven multi-effect systems
• Low-temperature operation: Evaporation at 70-85°C prevents volatilization of certain pharmaceutical compounds that would escape at higher temperatures
• Compact footprint: MVR systems require significantly less space than multi-effect or flash evaporation plants — critical for laboratory environments with limited installation area
• Scalability: From small laboratory units to large industrial systems, MVR technology scales efficiently without proportional energy cost increases

For the Uruguay pharmaceutical testing laboratory, these advantages translated directly into operational confidence: a treatment system that handles every contaminant type, operates economically, and delivers consistent ZLD performance regardless of daily testing variations.

WTEYA: MVR Evaporator Expertise You Can Trust

With nearly 20 years of experience in MVR evaporator design and manufacturing, WTEYA has commissioned systems across more than 30 countries — from pharmaceutical laboratories in South America to petrochemical plants in the Middle East, battery manufacturing facilities in Asia, and food processing operations in Europe.

Our 30,000 m² manufacturing base produces MVR evaporator systems ranging from compact laboratory-scale units to large industrial installations processing hundreds of cubic meters per day. Every system undergoes rigorous quality control, factory testing, and on-site commissioning by experienced technical engineers.

WTEYA offers comprehensive support throughout the project lifecycle:

• Custom engineering: System design tailored to your specific wastewater profile, flow rates, and regulatory requirements
• On-site commissioning: Professional technical team manages installation verification, wet testing, and performance validation
• Operator training: Complete training program for your local staff — covering daily operation, maintenance schedules, and troubleshooting
• Ongoing support: Remote monitoring, spare parts supply, and technical consultation available worldwide
• OEM & ODM services: Custom manufacturing for partners who need WTEYA quality under their own branding

Looking Ahead: Latin America Expansion

The successful Uruguay commissioning reinforces WTEYA's commitment to Latin America — a region where industrial wastewater treatment infrastructure is rapidly evolving and environmental regulations are tightening. Pharmaceutical manufacturing and testing is growing across Uruguay, Brazil, Argentina, and Chile, creating increasing demand for reliable, energy-efficient wastewater treatment solutions.

WTEYA is actively expanding our presence in the region, with ongoing projects in pharmaceutical, petrochemical, and battery industry sectors. Our MVR evaporator technology — proven across diverse effluent types and regulatory environments — is ready to meet Latin America's growing wastewater treatment needs.

If your facility faces complex wastewater treatment challenges — whether pharmaceutical, industrial, or laboratory — WTEYA's MVR evaporator technology delivers the efficiency, reliability, and compliance assurance you need. Contact our engineering team to discuss your specific requirements.

Frequently Asked Questions

Q: What is an MVR evaporator?

A: MVR (Mechanical Vapor Recompression) evaporator is an energy-efficient evaporation technology that reduces energy consumption by 30-50% compared to traditional evaporation.

Q: How much energy can MVR save?

A: MVR evaporators typically reduce energy consumption by 30-50% compared to traditional multi-effect evaporators, using electricity instead of steam.

Q: What is the difference between MVR and multi-effect evaporator?

A: MVR uses mechanical vapor recompression for energy efficiency, while multi-effect evaporators use multiple evaporation stages. MVR has lower operating costs.

Ready to Reduce Your Environmental Footprint?

Every day of delay costs money. Our rapid-response team can deliver a preliminary solution design within 48 hours.

Send us your wastewater data and let's start building your custom system today.

📲 WhatsApp: +86-1800 2840 855
📧 Email: info@wteya.com
🌐 Website: www.wteya.com